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Spencer B. King III, MD, MACC, Editor-in-Chief, JACC: Cardiovascular InterventionsW e are still receiving many good clinicalresearch papers on stenting, stentingtechnology, and stenting outcomes, but
you may notice that papers on structural heart dis-
ease and peripheral vascular disease sometimes
outnumber those on coronary interventions. The
advances in coronary interventions may seem
mature. Maybe we have gone so far that coronary
stenting is no longer a big deal. A cardiology friend
of mine just returned from a cruise up the coast of
Norway. One day at sea, the ship doctor asked him
to see a passenger who had chest pain. After an elec-
trocardiogram and enzymes showed abnormalities,
the passenger was lifted from the ship by helicopter
and delivered to a hospital in Trondheim where a
stent was placed in his 90% left anterior descending
coronary artery lesion. Three days later, the passen-
ger was again enjoying a cocktail on the main deck
while admiring the scenic Nordic coastline. Is this
no big deal? Are we becoming blasé about the
marvelous results that can be achieved with the latest
stent technology? What could go wrong? Restenosis,
the “soft underbelly” of angioplasty as Richard Myler
called it, continues to recede from our consciousness,
and that is a good thing. When it does come back it is
usually a benign visitor, and the main question is
which effective therapy should be used to correct it.
The other culprit that is much more sinister is, and
always has been, stent thrombosis. New stent tech-
nology, deployment techniques, and antithrombotic
therapy have made it rare, but when it comes to
call, it is devastating. Some studies show that stent
thrombosis is far below 1%, so it is easy to discount
it as a problem. This discounting, however, may itself
be a problem.
In this issue of JACC: Cardiovascular Interventions,
an excellent state-of-the-art paper reviews the prob-
lem of stent thrombosis from its early days to the
current state and emphasizes the various means ofavoiding this disaster (1). Yes, the stents are better
and the antiplatelet strategies may be better, but a
good measure of the improvement in outcomes re-
lates to the attention that has been paid to proper
stent deployment with the goal of complete deploy-
ment and apposition with smooth laminar ﬂow
through the treated segment. This remains one of the
most effective antithrombotic measures we have.
Nonetheless, stent thrombosis, and especially late
stent thrombosis, remains, and we must not become
too dependent on the stent or on the antiplatelet
drugs to bail out suboptimal deployment techniques.
Two other papers with accompanying editorials
explore the correlates and outcomes of stent throm-
bosis (2–5). With the low prevalence of stent throm-
bosis, it has been difﬁcult to provide strong evidence
for the magnitude and duration of antiplatelet ther-
apy. Much of the evidence is provided in the state-
of-the-art paper, and ongoing clinical investigation
continues to weigh the balance between adequate
antiplatelet therapy and bleeding risk.
It is not in the nature of interventional cardiology
or of those who develop the products we use to agree
that “they’ve gone about as far as they can go” (6).
New directions in stenting, including bioabsorbable
stents, bifurcation stents, self-expanding stents, and
the like, are mostly designed to reduce restenosis, but
their relationship to stent thrombosis needs careful
examination not only in clinical trials, but also in the
more complex situations in which they may be used
after general release. Keeping track of stent throm-
bosis is not an easy assignment, because many events
occur out of the hospital; weeks, months, or years
after implantation; and often at locations remote
from the hospital where the stent was originally
placed. Post-market surveillance methods are critical
for stent designs that are markedly different from
those with which we have extensive experience. We
may not have gone as far as we can go, but we have
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1203gone a long way toward mitigating stent thrombosis.
Future stent designs and materials should be held to
the high standard that has been established. As
operators become more conﬁdent in addressing more
complex lesions, they also must pay exquisite atten-
tion to technique, not only to achieve an initial result,
but also to protect the patient for years to come.
As JACC: Cardiovascular Interventions continues
to mature, we will try to reﬂect the issues of
greatest interest to practicing interventional cardi-
ologists, scientists, engineers, and researchers as the
ﬁeld itself matures and evolves. We are proud that
those of you continuing to investigate improve-
ments in stenting are submitting excellent studiesfor publication in this journal. Along with the surge
in structural heart and peripheral vascular sub-
missions, the continued interest in coronary stent-
ing has been a signiﬁcant factor in the recently
released impact factor of 7.44 (the highest for any
subspecialty journal in cardiology). We, the editors,
are pleased, but we also hope we have not gone as
far as we can go.
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